Background: Invasive micropapillary carcinoma (IMPC) is an aggressive variant of adenocarcinoma found in several organs. Recent studies showed that IMPC in colorectal cancer leads to poorer prognosis than conventional colorectal cancer; however, the influence of IMPC on outcomes remains unclear. The present study aimed to identify the clinicopathological characteristics of colorectal cancers with IMPCs, and to evaluate the prognostic significance of IMPCs per se Methods: We retrospectively analyzed data from 837 patients with colorectal cancer who underwent surgical treatment. We compared the clinicopathological characteristics and survival outcomes of colorectal cancer patients with IMPCs to those without. Results: Among 837 patients, 130 (16%) had an IMPC component, including 0 (0%) of 18, 9 (4.2%) of 215, 34 (13%) of 254, 59 (24%) of 249 and 28 (27%) of 101 patients with TNM Stages 0, I, II, III and IV, respectively. The 3-year disease-free survival (DFS) rates were significantly worse for Stage III patients with IMPC than for those without (55.3% vs. 78.7% respectively, P < 0.001), but not in patients with other stages. Multivariate analyses of patients with Stage III colorectal cancer found IMPC to be associated with significantly worse DFS (P = 0.026), as were high CEA levels, tumor budding and TNM staging. IMPC was only significantly associated with tumor invasion (P = 0.045) and venous invasion (P = 0.045) in Stage III tumors. Conclusions: Identifying IMPC components in Stage III colorectal cancer is crucial, as their presence is significantly associated with poorer survival.
Introduction
The prognostic assessment of colorectal cancers involves tumor, node and metastasis (TNM) staging, upon which therapeutic decisions are usually based. However, survival after surgery varies considerably among patients of similar-stage diseases; for example, the risk of recurrence among patients with Stage III colon cancer is between 15% and 50% (1) . The National Comprehensive Cancer Network ® (NCCN ® ) guidelines recommend adjuvant chemotherapy for all patients with Stage III colorectal cancer after curative resection (2) . However, factors that are predictive of the prognosis of patients with Stage III colorectal cancer have not been established; identification of such prognosticators ought to lead to more appropriate treatment choices and improved patient prognoses. Invasive micropapillary carcinoma (IMPC) has been described as a negative prognostic factor for breast, bladder and lung cancers, and is frequently associated with lymph node metastasis and adverse clinical outcomes (3) (4) (5) . IMPC in colorectal cancer has been classified as a subtype of adenocarcinoma that features small tumor cell clusters within stromal spaces mimicking vascular channels (6) . Colorectal cancer with IMPC has recently been shown to be more frequently associated with lymphovascular invasion, lymph node metastasis and aggressive biological and clinical behavior (7, 8) . However, past studies that compared colorectal cancers with IMPC to those without have produced inconsistent findings in terms of prognosis (9) (10) (11) . Because the association between IMPC and prognosis remains unclear, we analyzed the clinicopathological characteristics of colorectal cancers that contain an IMPC component, and evaluated the prognostic significance of IMPC.
Materials and methods

Patients
We retrospectively analyzed 837 patients with colorectal cancer in whom the primary lesion was completely resected between April 2009 and March 2015 at Hiroshima City Asa Citizens Hospital. Colorectal cancer patients with pathological Stages I-III underwent curative resection. All clinical data were collected from a prospective database. None of the patients had received preoperative chemotherapy or radiotherapy.
This study was approved by the Ethics Committee for Human Research of Hiroshima City Asa Citizens Hospital. Written informed consent for surgery and the use of clinical data was obtained from all patients.
Tissues and clinicopathological features
All surgically resected specimens were fixed in 10% formalin, serially cut into 5-7-mm-thick slices, and embedded in paraffin. At least 50% of the tumor areas on these slices were pathologically evaluated by staining with hematoxylin and eosin (H&E). The presence of an IMPC component was histopathologically evaluated in all stained slices.
IMPC was defined as a carcinoma composed of small clusters of tumor cells within stromal spaces that mimic vascular channels ( Fig. 1) as previously described (6) . IMPCs in colorectal cancer are usually a minor component of the entire lesion and are often present at its invasive edge (8) . The proportion of the IMPC component in each tumor was also evaluated, and a case was classified as IMPCpositive when a micropapillary component comprised at least 5% of the tumor, as described previously (7, 8) . Two pathologists (M.K. and H.M.) who were blinded to patient outcomes independently evaluated the pathologic indicators. In case of a discrepancy, the slides were reviewed again by both pathologists using a multiheaded microscope in order to achieve diagnostic consensus. To rule out adenocarcinoma with extensive lymphatic infiltration, histopathological examination was performed by using the D2-40 antibody (DAKO Cytomation, Glostrup, Denmark). Vascular invasion was assessed by Verhoeff's Van Gieson stain in almost all tumor sections where invasion was deeper than the mucosa. All tumors were staged according to the criteria of the American Joint Committee on Cancer (AJCC) TNM system (7th edition) (12) . The histological grade was also determined according to the AJCC recommendations as follows: low (gland formation ≥50% in tubular adenocarcinoma and papillary carcinoma) and high (gland formation <50% in tubular adenocarcinoma, mucinous adenocarcinoma, signet ring-cell carcinoma and undifferentiated carcinoma) (13) . Tumor budding was assessed on H&E-stained slides and defined as an isolated single cancer cell or a cluster comprising fewer than five cells, as previously described (14) . Buds were counted in a selected field exhibiting maximal budding intensity under ×20 magnification. Tumors were divided into two groups according to the number of budding foci: counts of 0-9 were classified as low-grade, while counts of 10 or more foci were classified as high-grade (15) .
The evaluated clinicopathological parameters of the patients included age at diagnosis, sex, the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), tumor location, preoperative bowel obstruction or perforation, tumor size, number of dissected lymph nodes, histological grade, invasion depth (pT stage), lymph node metastasis (pN stage), lymphatic invasion, venous invasion, tumor budding, TNM stage, adjuvant chemotherapy, presence or absence of recurrence, date of most recent followup and survival status.
Patient follow-up
All the patients were assessed at intervals for local control and distant metastases by physical examination, contrast computed tomography (CT) of the chest and abdominal cavity, and measurement of serum CEA and CA19-9 levels. In principle, these results were recorded at follow-up visits every 3 months during the first 2 years, every 6 months during the next 3 years, and annually thereafter when considered necessary. Colonoscopy was performed within 1 year of surgery, and once every 2-3 years thereafter. Patients in whom recurrence was suspected underwent contrast CT, enhanced magnetic resonance imaging of the liver and/or positron emission tomography. Recurrence was diagnosed pathologically (by surgical resection or biopsy) and/or radiologically.
Adjuvant chemotherapy in the form of oral UFT (tegafur/uracil)/ leucovorin (LV), capecitabine, intravenous 5-fluorouracil (5-FU)/LV, FOLFOX (oxaliplatin, 5-FU and leucovorin) and CapeOx (capecitabine and oxaliplatin) was administered for 6 months in selected patients based on physicians' recommendations and patients' preferences. In Japan, use of oxaliplatin-based chemotherapy for colon cancer in an adjuvant setting was not approved by the governmental health insurance system until August 2009. The treatment strategy after recurrence was decided at the discretion of the physicians.
Statistical analysis
All data were statistically analyzed using EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). It is a modified version of R commander (version 1.6-3) with functions that are frequently used in biostatistics. Statistically significant differences were analyzed using the χ 2 and Mann-Whitney U tests.
DFS was defined as the interval between surgery and relapse or death, whichever occurred first. OS was calculated as the interval between surgery and death from any cause. Correlations between the presence of an IMPC component and DFS were assessed using Cox proportional hazards models. The duration of DFS and OS was analyzed using the Kaplan-Meier method, and differences in DFS and OS were assessed using log-rank tests. A value of P < 0.05 was considered statistically significant.
Results
Pathological features of IMPC
Among 837 patients, 130 (16%) had an IMPC component; the breakdown according to stage is shown in Table 1 . The proportion of IMPC components ranged from 5% to >80% (Table 2) . The IMPC component comprised <20% of the tumor volume in the majority (94%) of the patients, and was most often located at the invasive front. Pure IMPC was not identified, although four tumors (one Stage I, two Stage III, and one Stage IV) comprised >80% IMPC. These four tumors were the only IMPC tumors that were detected by pre-surgical assessment via colonoscopy and tumor biopsy, which was performed in 815 of all 837 patients screened in this study (97%).
Survival analysis
The median follow-up duration for the 837 patients was 45 (range, 1-97) months. location, preoperative bowel obstruction or perforation, tumor size, histological grade, number of lymph nodes harvested, lymph node metastasis (pN stage), lymphatic invasion, tumor budding, TNM stage and adjuvant chemotherapy did not significantly differ between colorectal cancer patients with vs. without IMPCs. Fifty-eight patients (22%) developed recurrence. The initial recurrence was detected in the liver in 18 patients, lung in 18, peritoneum in 12, local site in 7, extra-regional lymph node in 5, and locoregional lymph node in 1. In four patients, recurrence in more than two organs was detected simultaneously. Among 23 patients with an IMPC component who experienced recurrence, 17 (74%) developed distant metastasis (liver, lung and extra-regional lymph node). The treatment after recurrence involved the resection of the metastatic site in 19 patients, systemic chemotherapy in 38, and best supportive care in 2. Five Stage III tumors in which the IMPC component comprised ≥20% did not recur during follow-up.
Univariate and multivariate analyses of DFS in patients with Stage III colorectal cancer
We analyzed various clinicopathological parameters to identify factors that predict DFS in patients with Stage III colorectal cancer. Univariate analysis revealed that high serum CEA levels (≥5 vs. <5 ng/ml, P < 0.001), invasion depth (T3-4 vs. T1-2, P = 0.015), lymph node metastasis (N2 vs. N1, P = 0.004), tumor budding (high-grade vs. low-grade, P < 0.001), TNM stage (IIIA vs. IIIB, P = 0.034; IIIA vs. IIIC, P = 0.005), and the presence of an IMPC component (P < 0.001) as significant predictors of DFS. Multivariate analysis revealed that high serum CEA levels (≥5 vs. <5 ng/ml, P = 0.001), tumor budding (high-grade vs. low-grade, P < 0.001), presence of an IMPC component (P = 0.026), and TNM stage (IIIA vs. IIIC, P = 0.037) were independent predictors of DFS (Table 4) .
Discussion
Recent studies have associated IMPC with lymphovascular invasion and an increased frequency of lymph node metastasis in colorectal cancer (7, 8, 16) . It has been posited that the inverted polarity of the cells that comprise the micropapillary nests with an 'inside-out' growth pattern, as reported previously (3), may be responsible for the tumor's high invasive potential. However, survival outcomes of colorectal cancer patients with IMPC have not been analyzed in detail. Xu et al. analyzed 30 patients diagnosed with colorectal cancer with IMPC and reported that the presence of an IMPC component predicts poorer survival in Stages I and II colorectal cancer, but not in Stages III and IV (9). Lino-Silva et al. observed worse 3-year survival rates among 15 patients with Stage III and IV colon cancers harboring IMPC components; however, IMPC was not a significant independent predictor of survival (10). Lee et al. reported that IMPC was an independent negative prognostic factor for all the patients in their cohort on multivariate analysis. Analysis of their patients when stratified by TNM stage revealed that the 5-year OS rates of Stage III colorectal cancer patients with IMPC (34 patients) were significantly lower than those of microsatellite stable carcinoma patients. The 5-year OS rates of their 15 Stages I-II colorectal carcinoma patients with IMPC were also worse than those of microsatellite stable carcinoma patients, although without statistical significance (11) . However, the sample size of their study (including the number of subjects in each TNM Stage) was small. Although it is evident that IMPC is more likely to be present in advanced stage colorectal cancers, its prognostic significance remains somewhat uncertain given the conflicting results of previous studies. The present study included 59 Stage III patients those tumors had IMPC components; we revealed a significant difference in 3-year DFS rates between patients with and without IMPC. Despite undergoing radical surgery and adjuvant chemotherapy, the survival rate of patients with Stage III colorectal cancer remains unsatisfactory. The NCCN ® guidelines recommend several adjuvant chemotherapy regimens for such patients (2) . Several large prospective trials have found that adding oxaliplatin to combinations of 5-FU and capecitabine improves DFS and OS rates among patients with Stage III colon cancer (17) (18) (19) . The rate of postoperative adjuvant chemotherapy did not differ between the two groups. However, only Stage III patients with IMPC components showed poor survival outcomes compared to those without IMPC components. Lee et al. suggested that the reason for this is that colorectal cancer with IMPC exhibits higher stem cell marker expression and comprises a greater proportion of tumor cells with stem-like features, which in turn can contribute to chemoresistance (11) .
In our study, we found that the presence of an IMPC component is an independent prognostic factor for DFS in patients with Stage III colorectal cancer, along with high CEA levels, tumor budding and TNM staging. Recently, tumor budding was recognized as a valuable prognostic indicator in colorectal cancer. The presence of tumor budding is an independent adverse prognostic factor in patients with Stage II colorectal cancer. However, the literature is unclear regarding the association between tumor budding and prognosis in Stage III patients because of conflicting reports (20) . In this study, we found that tumor budding is indeed an independent predictor of DFS in Stage III patients. Our findings therefore suggest that identification of an IMPC component is useful for stratifying patients with Stage III colorectal cancer according to their recurrence risk. However, the patients' OS in our study did not significantly differ according to the presence of an IMPC component; this may be attributed the relatively short follow-up period.
An IMPC component was identified in 16% of all colorectal cancers in the present study, whereas pure IMPC tumors were not found. These results are similar to previous findings (7, 8) . The incidence of an IMPC component was higher in advanced tumors. Studies have shown that IMPCs are usually a minor component located at the invasion front of a tumor. Verdu et al. reported that increasing the number of routinely assessed sections, especially of the tumor's infiltrative edge, are likely to increase the incidences of detecting a colorectal IMPC component (7) . However, the proportion of IMPC-containing tumors in the present study, which included a considerable number of routine sections of advanced-stage tumors, was similar to those in previous studies (7, 8 ). An IMPC component was detected in only four preoperative biopsy specimens from among 815 patients; as the IMPC component occupied ≥80% of the tumor in each of these patients, IMPCs of smaller proportions may not be detectable at the invasive front preoperatively.
An IMPC component of any size in breast carcinoma tends to invade lymphatic vessels and metastasize to axillary lymph nodes; therefore, the importance of detecting such a component in conventional carcinoma is critical (3). Five patients with Stage III colorectal cancer in the present study who had IMPC components that comprised ≥20% of their tumors did not experience a recurrence during the follow-up period. At the same time, much smaller IMPC components in Stage III colorectal tumors were associated with worse survival. These data were consistent with the findings of Kim et al., who reported that the IMPC proportion did not affect the prognosis (11) .
This study may be limited by its retrospective design and relatively short follow-up period. We also did not evaluate the effect of adjuvant chemotherapy regimens.
In conclusion, having an IMPC component of any size was an independent negative prognostic factor in patients with Stage III colorectal cancer. Therefore, detecting an IMPC component in advanced colorectal cancer is critical for assessing both patient prognosis and survival.
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